EZH2 and cancer: Survival analyses using the TCGA PAM50-based dataset for human basal-like cancers showed that patients with low EZH2 (Fig. 5F), high NFATC1 (Fig. 5G) or low (EZH2/NFATC1)-ratio (Fig. 5H) have a worse prognosis compared to EZH2 high, NFATC1 low or high (EZH2/NFATC1)-ratio patients.